Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Gyre Therapeutics (GYRE) Equity Average (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Equity Average for 15 consecutive years, with $115.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Equity Average rose 20.61% to $115.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $115.7 million, a 20.61% increase, with the full-year FY2024 number at $56.2 million, up 30.39% from a year prior.
  • Equity Average was $115.7 million for Q3 2025 at Gyre Therapeutics, down from $116.9 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $116.9 million in Q2 2025 to a low of $43.3 million in Q1 2022.
  • A 5-year average of $77.5 million and a median of $77.4 million in 2023 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: tumbled 51.96% in 2022, then skyrocketed 98.33% in 2024.
  • Gyre Therapeutics' Equity Average stood at $60.1 million in 2021, then fell by 15.48% to $50.8 million in 2022, then fell by 2.29% to $49.6 million in 2023, then soared by 98.33% to $98.4 million in 2024, then increased by 17.52% to $115.7 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Equity Average are $115.7 million (Q3 2025), $116.9 million (Q2 2025), and $101.4 million (Q1 2025).